Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers (DOI:10.1016/j.vaccine.2007.12.024);Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

Vaccine

Volumn 26, Issue 8, 2008, Pages 1098-1110

  Wang, Shixia ^a   Kennedy, Jeffrey S ^a   West, Kim ^a   Montefiori, David C ^c   Coley, Scott ^a   Lawrence, John ^a   Shen, Siyuan ^a   Green, Sharone ^a   Rothman, Alan L ^a   Ennis, Francis A ^a   Arthos, James ^d   Pal, Ranajit ^b   Markham, Phillip ^b   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

DNA vaccine; HIV 1; Phase I clinical trial; Prime boost; Recombinant protein vaccine

Indexed keywords

DNA VACCINE; DP6 001; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; PRIMER DNA; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG FORMULATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; LEUKOCYTOCLASTIC VASCULITIS; MALE; MULTIGENE FAMILY; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; T LYMPHOCYTE;

EID: 39149109930     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.060     Document Type: Erratum

References (48)

1. HIV/AIDS JUNPo. Report on the global AIDS epidemic 2006. 2006 [cited 2007 14 February]; Availablefrom: http://data.unaids.org/pub/GlobalReport/2006/2006_GR_CH02_en.pdf.
2. Gorse G.J., Corey L., Patel G.B., Mandava M., Hsieh R.H., Matthews T.J., et al. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 15 2 (1999) 115-132
3. Kim J.H., Pitisuttithum P., Kamboonruang C., Chuenchitra T., Mascola J., Frankel S.S., et al. Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res Hum Retroviruses 19 9 (2003) 807-816
4. Lee S.A., Orque R., Escarpe P.A., Peterson M.L., Good J.W., Zaharias E.M., et al. Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates. Vaccine 20 3-4 (2001) 563-576
5. Nitayaphan S., Khamboonruang C., Sirisophana N., Morgan P., Chiu J., Duliege A.M., et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais. AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine 18 15 (2000) 1448-1455
6. Ackers M.L., Parekh B., Evans T.G., Berman P., Phillips S., Allen M., et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis 187 6 (2003) 879-886
7. Beddows S., Lister S., Cheingsong R., Bruck C., and Weber J. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J Virol 73 2 (1999) 1740-1745
8. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173 2 (1996) 340-348
9. Bures R., Gaitan A., Zhu T., Graziosi C., McGrath K.M., Tartaglia J., et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 16 18 (2000) 2019-2035
10. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191 5 (2005) 666-677
11. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., and Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 5 (2005) 654-665
12. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E.G., et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85 Pt 4 (2004) 911-919
13. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80 10 (2006) 4717-4728
14. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194 12 (2006) 1650-1660
15. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194 12 (2006) 1638-1649
16. Pal R., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., Hocker L., et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348 2 (2006) 341-353
17. Pal R., Wang S., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 34 5-6 (2005) 226-236
18. Cristillo A.D., Wang S., Caskey M.S., Unangst T., Hocker L., He L., et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 346 1 (2006) 151-168
19. Wang S., Arthos J., Lawrence J.M., Van Ryk D., Mboudjeka I., Shen S., et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 79 12 (2005) 7933-7937
20. Beddows S., Schulke N., Kirschner M., Barnes K., Franti M., Michael E., et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 79 14 (2005) 8812-8827
21. Srivastava I.K., Ulmer J.B., and Barnett S.W. Role of neutralizing antibodies in protective immunity against HIV. Hum Vaccin 1 2 (2005) 45-60
22. Lian Y., Srivastava I., Gomez-Roman V.R., Zur Megede J., Sun Y., Kan E., et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol 79 21 (2005) 13338-13349
23. Vajdy M., Singh M., Kazzaz J., Soenawan E., Ugozzoli M., Zhou F., et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 20 11 (2004) 1269-1281
24. Leung L., Srivastava I.K., Kan E., Legg H., Sun Y., Greer C., et al. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. Aids 18 7 (2004) 991-1001
25. Shu Y., Winfrey S., Yang Z.Y., Xu L., Rao S.S., Srivastava I., et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25 8 (2007) 1398-1408
26. Law M., Cardoso R.M., Wilson I.A., and Burton D.R. Antigenic immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol 81 8 (2007) 4272-4285
27. Wang S., Pal R., Mascola J.R., Chou T.H., Mboudjeka I., Shen S., et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350 1 (2006) 34-47
28. Pal R., Yu Q., Wang S., Kalyanaraman V.S., Nair B.C., Hudacik L., et al. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine 24 8 (2006) 1225-1234
29. Kennedy J.S., Frey S.E., Yan L., Rothman A.L., Cruz J., Newman F.K., et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 190 7 (2004) 1286-1294
30. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. In: Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W., and Coico R. (Eds). Current Protocols in Immunology (2004), John Wiley & Sons pp. 12.1.1-1.5
31. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 16 (2005) 10108-10125
32. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80 23 (2006) 11776-11790
33. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100 7 (2003) 4144-4149
34. Mulligan M.J., Russell N.D., Celum C., Kahn J., Noonan E., Montefiori D.C., et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses 22 7 (2006) 678-683
35. Wang B., Ugen K.E., Srikantan V., Agadjanyan M.G., Dang K., Refaeli Y., et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90 9 (1993) 4156-4160
36. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 5514 (2001) 69-74
37. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 5491 (2000) 486-492
38. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
39. Yasutomi Y., Robinson H.L., Lu S., Mustafa F., Lekutis C., Arthos J., et al. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 70 1 (1996) 678-681
40. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178 1 (1998) 92-100
41. Ugen K.E., Nyland S.B., Boyer J.D., Vidal C., Lera L., Rasheid S., et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 16 19 (1998) 1818-1821
42. Pitisuttithum P. HIV-1 prophylactic vaccine trials in Thailand. Curr HIV Res 3 1 (2005) 17-30
43. Berman P.W., Huang W., Riddle L., Gray A.M., Wrin T., Vennari J., et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 265 1 (1999) 1-9
44. Bures R., Morris L., Williamson C., Ramjee G., Deers M., Fiscus S.A., et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 76 5 (2002) 2233-2244
45. Deeks S.G., Schweighardt B., Wrin T., Galovich J., Hoh R., Sinclair E., et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 80 12 (2006) 6155-6164
46. Tang D.C., DeVit M., and Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356 6365 (1992) 152-154
47. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 5102 (1993) 1745-1749
48. Robinson H.L., Hunt L.A., and Webster R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11 9 (1993) 957-960